Alan Edmund Walts - 16 Oct 2024 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Sumit Aggarwal, Attorney-in-Fact for Alan Edmund Walts
Issuer symbol
N/A
Transactions as of
16 Oct 2024
Net transactions value
$0
Form type
4
Filing time
17 Oct 2024, 16:02:21 UTC
Previous filing
26 Jan 2024
Next filing
28 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELOX Common Stock Award $0 +12,000 +1274% $0.000000 12,942 16 Oct 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This restricted stock grant was made pursuant to the Issuer's 2018 Equity Incentive Plan and vests as to 50% of the shares on October 16, 2025 and in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

Remarks:

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share counts herein reflect the reverse stock split.